Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 31 Dec 2024
3-year disease-free survival rate was 96% with blinatumomab versus 87.9% with chemo alone
Read Full NewsA novel oral ketamine drug shows a signal for reducing depressive symptoms with minimal dissociative effects.
Men who receive personalized estimates of the likelihood of raised prostate-specific antigen levels are more likely to decide to get screening than those who receive general information on pros and cons.
Upadacitinib and infliximab offer rapid relief from symptoms in biologic-naive patients with moderate-to-severe ulcerative colitis.
Clinicians and patients are already relying on AI, while hospitals are still building the oversight to keep up.
A culturally tailored lifestyle program improves cognition significantly more than standard health advice among older adults at risk for dementia across Latin America.
People with intellectual disabilities who have physical health problems or sensory impairments face a higher risk for challenging behaviours.
Rimegepant is safe and effective in patients with migraine not responding to multiple prior preventive therapies, a real-world study shows.
1.
Researchers discuss HER2-low and HER2-zero in breast cancer
2.
A healthier lifestyle after bowel screening shown to prevent bowel cancer
3.
EMA Backs Breast Cancer SERD After FDA No Vote
4.
WHO Warns Loosely Regulated Nicotine Pouches Risk Youth Addiction
5.
United States Lung Cancer Screening Rates Remain Low. s. in particular in the South.
1.
Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment
2.
Elevating Hematology Oncology: Modern Approaches for Smarter Diagnosis and Treatment
3.
Cancer Cachexia: Emerging Therapeutic Strategies
4.
Single-Cell Lineage Tracing in Hematology: Decoding the Cellular Blueprint of Blood Disorders
5.
Case Study: Artificial Intelligence in Early Cancer Detection
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
2.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
3.
Efficient Management of First line ALK-rearranged NSCLC - Part II
4.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
5.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge